Učitavanje...
Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
Anifrolumab (anifrolumab) is an antagonist human monoclonal antibody that targets interferon α receptor 1 (IFNAR1). Anifrolumab has been developed to treat autoimmune diseases and is currently in clinical trials. To decipher the molecular basis of its mechanism of action, we engaged in multiple epit...
Spremljeno u:
| Izdano u: | MAbs |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622752/ https://ncbi.nlm.nih.gov/pubmed/25606664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1007810 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|